Similar articles

• Chemotherapy-associated Raynaud's phenomenon in a two-year-old girl.

  McGuire WA, Passo MH, Weetman RM. McGuire WA, et al. Med Pediatr Oncol. 1985;13(6):392-4. doi: 10.1002/mpo.2950130619. Med Pediatr Oncol. 1985. PMID: 2413340
• Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin.

  Hansen SW, Olsen N, Rossing N, Rørth M. Hansen SW, et al. Ann Oncol. 1990 Jul;1(4):289-92. doi: 10.1093/oxfordjournals.annonc.a057750. Ann Oncol. 1990. PMID: 1702313
• Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer.

  Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Berger CC, et al. Eur J Cancer. 1995 Dec;31A(13-14):2229-38. doi: 10.1016/0959-8049(95)00460-2. Eur J Cancer. 1995. PMID: 8652248
• Vascular toxicity associated with chemotherapy for testicular cancer.

  Gerl A. Gerl A. Anticancer Drugs. 1994 Dec;5(6):607-14. doi: 10.1097/00001813-199412000-00001. Anticancer Drugs. 1994. PMID: 7534146 Review.
• [Raynaud's phenomenon and finger necrosis after treatment of ovarian seminoma with bleomycin, vinblastine and 5-fluorouracil].

  Werquin S, Kacet S, Caron J, Lacroix D, Libersa C, Coget JM, Lekieffre J. Werquin S, et al. Ann Cardiol Angeiol (Paris). 1987 Oct;36(8):409-12. Ann Cardiol Angeiol (Paris). 1987. PMID: 2445238 Review. French.